Anti-angiogenic ophthalmic agents 

Anti-angiogenic ophthalmic agents act as vascular endothelial growth factor (VEGF) antagonists. When retinal pigment cells become ischemic and dry up VEGF stimulates generation of new blood vessels by a process called neovascularization. During the generation of new blood vessels in the retina, if the blood vessels do not generate properly it causes leaking. This can lead to loss of vision.

Anti-angiogenic ophthalmic agents are used to stop neovascularization in age related macular degeneration.

What are Anti-angiogenic ophthalmic agents? Anti-angiogenic ophthalmic agents act as vascular endothelial growth factor (VEGF) antagonists. When retinal pigment cells become ischemic and dry up VEGF stimulates generation of new blood vessels by a process called neovascularization.

Angiogenesis means the growth of new blood vessels. So anti angiogenic drugs are treatments that stop tumours from growing their own blood vessels. If the drug is able to stop a cancer from growing blood vessels, it might slow the growth of the cancer or sometimes shrink it.